Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
Author: Smith, D.
Smith, M.
Sweeney, C.
Elfiky, A.
Logothetis, C.
Corn, P.
Vogelzang, N.
Small, E.
Harzstark, A.
Gordon, M.
Vaishampayan, U.
Haas, N.
Spira, A.
Lara, P.
Lin, C.
Srinivas, S.
Sella, A.
Schöffski, P.
Scheffold, C.
Weitzman, A.
et al.
Citation: Journal of Clinical Oncology, 2013; 31(4):412-419
Publisher: American Society of Clincal Oncology
Issue Date: 2013
ISSN: 0732-183X
Statement of
David C. Smith, Matthew R. Smith, Christopher Sweeney, Aymen A. Elfiky, Christopher Logothetis, Paul G. Corn, Nicholas J. Vogelzang, Eric J. Small, Andrea L. Harzstark, Michael S. Gordon, Ulka N. Vaishampayan, Naomi B. Haas, Alexander I. Spira, Primo N. Lara Jr, Chia-Chi Lin, Sandy Srinivas, Avishay Sella, Patrick Schöffski, Christian Scheffold, Aaron L. Weitzman, and Maha Hussain
Abstract: Abstract not available
Keywords: Biomarkers, Tumor
Rights: © 2012 by American Society of Clinical Oncology
DOI: 10.1200/JCO.2012.45.0494
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.